TABLE 2.
Characteristics of patients with proven and probable IA.
IA group and patient no. | Sexa | Underlying disorderb | Neutropenia during the diagnosisc | Steroids >14 daysc | Computed tomography scan result | Positive samples/total samples | Site of fungal cultured | Direct resultse | Culture result | Treatment | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|
Proven IA | |||||||||||
1 | F | AML | + | + | Halo sign | 0/9 | Lung biopsy | Hyphae | A. fumigatus | L AmB | Survival |
2 | F | AML | + | − | Sinusitis plus osteolysis | 0/10 | Sinus (bone) | Hyphae | A. terreus | L AmB plus Itra (S) | Survival |
3 | M | NHL | − | − | Sinusitis plus osteolysis | 0/3 | Sinus (bone) | Hyphae | A. fumigatus | Itra (S) | Death |
Probable IAg | |||||||||||
4 | M | CLL | + | + | Halo sign | 2/2 | BAL | Hyphae | A. fumigatus | AmB | Death |
5 | M | AL | + | − | Halo plus necrosis | 2/5 | BA | Hyphae | Negative | AmB | Death |
6 | M | NHL (2) | + | + | Sinusitis | 4/10 | Nostril | Hyphae | A. flavus | AmB | Death |
7 | F | AML | + | − | Pulmonary infiltrate | 4/4 | BA | Hyphae | A. fumigatus | AmB | Death |
8 | M | CLL | − | − | Halo sign | 5/5 | Trachea | Hyphae | A. fumigatus | L AmB | Death |
9 | M | Kidney Tx | − | + | Bilateral infiltrate | 2/3 | Sputum, BA | Hyphae | A. fumigatus | L AmB | Death |
10 | F | AML (1) | + | − | Halo sign | 7/13 | Sputum, BA | No hyphae | Negative | L AmB | Survival |
11 | M | AML | + | − | Halo sign | 3/3 | Sputum | Hyphae | A. fumigatus | L AmB | Survival |
12 | F | AML (2) | + | − | Pulmonary necrosis | 3/6 | Sputum, BA | No hyphae | Negative | Itra | Death |
13 | F | NHL | + | + | Cavitation | 2/3 | Sputum, BA | Hyphae | A. fumigatus | AmB | Death |
14 | M | CML (1) | + | − | Pulmonary infiltrate | 6/10 | Sputum | No hyphae | Negative | AmB | Survival |
15 | M | AML | + | − | Pulmonary infiltrate | 3/9 | BAL, BA | Hyphae | A. fumigatus | AmB plus Itra | Survival |
16 | F | NHL | + | + | Halo sign | 3/3 | BA, trachea | Hyphae | A. fumigatus | AmB | Death |
17 | F | AML (2) | − | + | Pulmonary nodules | 4/7 | BAL, BA | Hyphae | Negative | AmB | Death |
18 | F | CLL (1) | + | + | Bilateral infiltrate | 2/2 | BAL, BA | Hyphae | A. fumigatus | Itra | Survival |
19 | M | CML | + | − | Pulmonary nodules | 6/6 | Sputum | Hyphae | Negative | AmB | Survival |
20 | M | NHL | − | − | Pulmonary infiltrate plus meningitis | 2/3 | CSF | No hyphae | Negative | AmB plus Itra | Survival |
Probable IAi | |||||||||||
21 | M | NHL | + | − | Halo sign | 0/5 | BA | Hyphae | A. fumigatus | AmB | Death |
22 | F | AML | + | + | Infiltrate plus nodules | 0/4 | Sputum | Hyphae | A. fumigatus | AmB | Death |
23 | M | NHL | + | + | Halo sign | 0/2 | Sputum | Hyphae | A. fumigatus | AmB | Death |
24 | F | AML | + | − | Pulmonary nodules | 0/6 | Sputum | Hyphae | A. flavus | AmB | Death |
25 | M | MDS | − | − | Halo sign | 0/4 | BA | Hyphae | A. fumigatus | AmB | Death |
26 | M | NHL | + | + | Pulmonary nodules | 0/6 | BAL, BA | Hyphae | A. fumigatus | AmB | Death |
27 | M | AML (2) | − | + | Pulmonary nodules | 0/3 | BAL, BA | Hyphae | A. fumigatus | AmB | Death |
28 | M | Liver Tx | + | − | Cavitation | 0/5 | Sputum, BA | Hyphae | A. fumigatus | L AmB plus Itra | Survival |
29 | M | CLL | − | + | Halo sign | 0/3 | BAL, BA | Hyphae | A. fumigatus | AmB | Survival |
30 | F | NHL (2) | + | + | Halo sign | 0/3 | BAL | Hyphae | NIh | AmB | Survival |
31 | M | Severe CBPO | − | + | Cavitation | 0/3 | Trachea | Hyphae | A. fumigatus | AmB | Death |
32 | M | Pulmonary Tx | + | − | Pulmonary infiltrate | 0/3 | BAL, BA | Hyphae | A. fumigatus | Itra | Survival |
33 | M | Severe CBPO | − | + | Pulmonary nodules | 0/2 | BA | Hyphae | A. fumigatus | Itra | Survival |
34 | F | AML | + | − | Cavitation | 0/2 | BA | Hyphae | A. flavus | AmB | Survival |
M, male, F, female.
AML, acute myeloid leukemia; NHL, non-Hodgkin's lymphoma; CLL, chronic lymphocytic leukemia; AL, acute leukemia; MDS, myelodysplastic syndrome; Tx, transplantation; CBPO, chronic brondhopulmonary obstruction; (1), autologous bone marrow transplantation; (2), allogeneic bone marrow transplantation.
+, Present; −, absent.
BAL, bronchoalveolar lavage; BA, bronchoaspiration; CSF, cerebral spinal fluid.
Presence of separate hyphae on direct microscopic observations.
AmB, amphotericin B; L AmB, liposomial amphotericin B; Itra, itraconazole; (S), surgical resection.
With positive antigenemia.
NI, Aspergillus species not identified.
With negative antigenemia.